Date | Operating Income | EBIT | EBITDA | Net Income |
---|
CEO | Mr. Marc A. Stapley |
IPO Date | Oct. 30, 2013 |
Location | United States |
Headquarters | 6000 Shoreline Court |
Employees | 815 |
Sector | Health Care |
Industries |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Past 5 years
USD 39.01
USD 13.23
USD 12.60
USD 1.94
USD 10.43
USD 7.26
USD 36.67
USD 35.62
USD 53.94
USD 16.86
USD 5.77
USD 25.38
USD 45.23
USD 10.49
USD 14.91
USD 22.74
USD 4.84
USD 12.48
USD 3.09
StockViz Staff
January 15, 2025
Any question? Send us an email